AVX901, an amplifying mRNA vaccine based on a self-amplifying VEEV vector encoding HER2, has completed phase I clinical trial in the treatment of HER2+ breast cancer, and the phase II clinical trial for its concomitant use with pembrolizumab is currently in the recruitment stage (50). This evidence concerns the gene ERBB2 and breast carcinoma.